/HBPCF
HBPCF Stock - Helix BioPharma Corp.
Healthcare|BiotechnologyOTC
$1.73+0.00%
+$0.00 (+0.00%) • Dec 19
80
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.90
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for HBPCF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.71 – $1.75
TARGET (TP)$1.99
STOP LOSS$1.59
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.63
52W High$1.73
52W Low$0.45
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-7,217 | N/A | $-13,000 | $-12,000 | $-173,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-3,915,602 | $-9,371 | $-6,326,000 | $-6,537,000 | $-9,611,000 |
| Net Income | $-3,756,812 | $-9,264 | $-6,290,000 | $-6,563,000 | $-8,038,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.07 | $-0.00 | $-0.03 | $-0.04 | $-0.06 |
Company Overview
Helix BioPharma Corp. operates as an immune-oncology company in Canada. The company is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
HBPCFBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.01
Q4 2025
EPS Surprise History
Q2 24
No data
Q2 24
No data
Q4 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q4 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 12, 2026 | — | — | — | — |
Q4 2025 | Dec 12, 2025 | — | $-0.01 | — | — |
Q4 2025 | Oct 16, 2025 | — | $-0.01 | — | — |
Q2 2025 | Jun 16, 2025 | — | $-0.02 | — | — |
Q1 2025 | Mar 14, 2025 | — | $-0.10 | — | — |
Q4 2024 | Dec 16, 2024 | — | $-0.02 | — | — |
Q4 2024 | Oct 24, 2024 | — | $-0.08 | — | — |
Q2 2024 | May 13, 2024 | — | $-0.01 | — | — |
Q2 2024 | Apr 29, 2024 | — | $-0.00 | — | — |
Q4 2023 | Dec 14, 2023 | — | $-0.05 | — | — |
Q4 2023 | Oct 27, 2023 | — | $-0.05 | — | — |
Q2 2023 | Jun 14, 2023 | — | $-0.05 | — | — |
Q1 2023 | Mar 15, 2023 | — | $-0.05 | — | — |
Q4 2022 | Dec 14, 2022 | — | $-0.05 | — | — |
Q4 2022 | Oct 31, 2022 | — | $-0.01 | — | — |
Q2 2022 | Jun 14, 2022 | — | $-0.05 | — | — |
Q1 2022 | Mar 16, 2022 | — | $-0.05 | — | — |
Q4 2021 | Dec 15, 2021 | — | $-0.05 | — | — |
Q4 2021 | Dec 9, 2021 | — | $-0.10 | — | — |
Q2 2021 | Jun 14, 2021 | — | $-0.10 | — | — |
Latest News
Loading news...
Frequently Asked Questions about HBPCF
What is HBPCF's current stock price?
Helix BioPharma Corp. (HBPCF) is currently trading at $1.73 per share. The stock has moved +0.00% today.
What is the analyst price target for HBPCF?
No analyst price targets are currently available for this stock.
What sector is Helix BioPharma Corp. in?
Helix BioPharma Corp. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is HBPCF's market cap?
Helix BioPharma Corp. has a market capitalization of $0.13 billion, making it a small-cap company.
Does HBPCF pay dividends?
No, Helix BioPharma Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACHFF
Arch Biopartners Inc.
$0.89
Mkt Cap: $0.1B
CLTEF
Calliditas Therapeutics AB (publ)
$0.55
Mkt Cap: $0.0B
INNMF
Amplia Therapeutics Limited
$0.08
Mkt Cap: $0.0B
OTLC
Oncotelic Therapeutics, Inc.
$0.09
Mkt Cap: $0.0B
PSYBF
PsyBio Therapeutics Corp.
$0.00
Mkt Cap: $0.0B
RLFTF
Relief Therapeutics Holding AG
$2.70
Mkt Cap: $0.0B
RLFTY
MindMaze Therapeutics Holding S.A. Sponsored ADR
$3.65
Mkt Cap: $0.0B
TCNAF
TransCanna Holdings Inc.
$0.00
Mkt Cap: $0.0B
VICP
Vicapsys Life Sciences, Inc.
$1.50
Mkt Cap: $0.0B
ZIVO
ZIVO Bioscience, Inc.
$9.98
Mkt Cap: $0.0B
Explore stocks similar to HBPCF for comparison